Dyslipidaemia is an umbrella term for abnormal levels of fats in the blood, specifically cholesterol and triglycerides. It is one of the most firmly established risk factors for heart disease and stroke, and it affects a substantial share of adults worldwide. The condition is not a single number being too high; it can involve elevated LDL cholesterol, elevated triglycerides, low HDL cholesterol, or some combination of all three. What makes dyslipidaemia tricky is that it produces no symptoms on its own, so it quietly accelerates arterial damage for years before anything goes wrong.
What the Numbers Actually Mean
A standard lipid panel, drawn after an overnight fast, measures four things: total cholesterol, LDL cholesterol (often called “bad” cholesterol), HDL cholesterol (“good” cholesterol), and triglycerides. Dyslipidaemia is generally defined as having any one of the following: total cholesterol at or above 200 mg/dL, LDL cholesterol at or above 100–130 mg/dL (the exact cutoff depends on your cardiovascular risk), triglycerides at or above 150 mg/dL, or HDL cholesterol below 40 mg/dL for men and below 50 mg/dL for women.1Circulation. Abstract P040: Dyslipidemia And The Incidence Of Subclinical And Clinical Cardiovascular Disease In Adolescents And Young Adults: The Strong Heart Family Study (SHFS) You can also be classified as having dyslipidaemia if you are already taking a lipid-lowering drug, regardless of what your current numbers look like.
These cutoffs are not arbitrary lines drawn for convenience. They reflect the levels at which population-level evidence shows cardiovascular risk begins to climb. But they are also simplified, and a growing number of researchers argue that standard LDL cholesterol measurements miss part of the picture. Apolipoprotein B, or apoB, is a protein found on every LDL particle and on other harmful lipoprotein particles. Because apoB gives a direct count of the number of damaging particles circulating in your blood, multiple expert groups now consider it a more accurate and precise marker than LDL cholesterol alone.2PubMed Central. Standardization of Apolipoprotein B, LDL-Cholesterol, and Non-HDL-Cholesterol In practice, your doctor may still rely on the standard panel, but if your triglycerides are high or your LDL and apoB seem to tell different stories, asking about apoB or non-HDL cholesterol can clarify your actual risk.3PubMed. Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk
What Causes Dyslipidaemia
The causes split into two broad categories: genetic and acquired. Most people with abnormal lipids have a mix of both, with their genes setting a baseline and their lifestyle nudging the numbers higher or lower.
Genetic Causes
The most dramatic genetic form is familial hypercholesterolaemia, or FH, which sends LDL cholesterol to dangerously high levels from birth. The most common cause of FH is a mutation in the gene encoding the LDL receptor, the protein on liver cells that pulls LDL out of the bloodstream. Mutations in two other genes, apolipoprotein B and PCSK9, can produce a similar picture.4PubMed Central. The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations People who inherit one copy of a faulty gene (heterozygous FH) typically have LDL levels roughly double the normal range; those who inherit two copies (homozygous FH) can have LDL levels four to six times higher and may develop heart disease in childhood.
Not everyone with very high LDL has a single identifiable mutation, though. A large number of common genetic variants each nudge LDL cholesterol upward by a small amount. When someone inherits an unlucky combination of many of these variants, the cumulative effect can mimic FH-level cholesterol without any single rare mutation being responsible.5PubMed Central. The clinical applicability of polygenic risk scores for LDL-cholesterol: considerations, current evidence and future perspectives In genetic studies of people with severe hypercholesterolaemia, those who carried a known FH mutation were especially likely to also have a low polygenic risk score, suggesting the single mutation was doing most of the heavy lifting. Meanwhile, carriers without a detectable mutation were more likely to have a high polygenic score, meaning many small-effect variants were adding up.6PubMed. Polygenic Risk Score for Low-Density Lipoprotein Cholesterol Is Associated With Risk of Ischemic Heart Disease and Enriches for Individuals With Familial Hypercholesterolemia
Acquired Causes
Diet is the most obvious acquired contributor. Diets high in saturated fat tend to raise LDL cholesterol, while replacing saturated fat with unsaturated fat lowers LDL and can also bring down triglycerides in people who are insulin-resistant.7PubMed. Dietary fat, insulin sensitivity and the metabolic syndrome But diet is only one lever. Obesity, physical inactivity, type 2 diabetes, hypothyroidism, kidney disease, excessive alcohol use, and certain medications (corticosteroids, some blood pressure drugs, and antiretrovirals, among others) can all distort the lipid profile. In clinical practice, these secondary causes should be checked for before attributing someone’s dyslipidaemia solely to genetics or diet, because treating the underlying condition often improves the lipid numbers on its own.
How Dyslipidaemia Damages the Body
The central danger of dyslipidaemia is atherosclerosis, the slow buildup of fatty plaques inside artery walls. LDL particles penetrate the inner lining of arteries, trigger inflammation, and set off a cycle of immune cell accumulation, tissue death, scarring, and calcification that gradually narrows the vessel and can eventually rupture, causing a heart attack or stroke.8PubMed Central. Mechanisms of plaque formation and rupture
A major European Atherosclerosis Society consensus statement, drawing on meta-analyses of over 200 prospective cohort studies, genetic studies, and randomized trials involving more than two million participants, confirmed that the link between LDL cholesterol and cardiovascular disease follows a consistent, dose-dependent pattern: the higher the LDL and the longer the exposure, the greater the risk.9European Heart Journal. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies This is not just a correlation. Genetic studies that randomly assign people to higher or lower lifetime LDL levels, and drug trials that lower LDL by different mechanisms, all point in the same direction.
What makes this especially important is that the damage is cumulative. Research tracking LDL exposure over time has found that the total amount of LDL your arteries have been exposed to across decades predicts heart disease risk better than a single snapshot measurement. People who keep LDL low throughout young adulthood and middle age have lower lifetime rates of coronary heart disease at every level of midlife LDL, with no obvious safe threshold below which further lowering stops helping.10JAMA Cardiology. Association Between Cumulative Low-Density Lipoprotein Cholesterol Exposure During Young Adulthood and Middle Age and Risk of Cardiovascular Events The rate at which LDL exposure accumulates also matters independently; a steeper rise in LDL over time carries additional risk beyond the total.11PubMed. Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk
Triglycerides carry their own risks, distinct from LDL. Moderately elevated triglycerides are associated with increased cardiovascular risk, but severely elevated levels (typically above 500 mg/dL) pose an additional, more immediate threat: acute pancreatitis. When triglycerides climb that high, large fat-carrying particles can thicken the blood flowing through the pancreas, causing blockages, tissue damage, and a painful inflammatory crisis that requires emergency treatment.12Clinical Chemistry. Hypertriglyceridemia-Associated Pancreatitis: New Concepts and Potential Mechanisms
The Hidden Risk Factor Most People Have Never Heard Of
Even after LDL and triglycerides are brought under control, some people still develop cardiovascular disease. Part of this so-called residual risk comes from lipoprotein(a), or Lp(a), a genetically determined lipoprotein that standard lipid panels do not measure. Elevated Lp(a) increases the risk of heart disease, heart attack, aortic valve stenosis, and heart failure independently of LDL cholesterol, meaning you can have textbook-perfect LDL and still face elevated risk if your Lp(a) is high.13PubMed Central. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives
Roughly 20 to 25 percent of the global population has elevated Lp(a), and those individuals face about two to three times the risk of heart attack and aortic valve stenosis compared with those who have low levels.14American Journal of Preventive Cardiology. Rethinking cardiovascular risk: The emerging role of lipoprotein(a) screening Lp(a) levels are overwhelmingly driven by genetics, with roughly 70 to over 90 percent of the variation between individuals being inherited. Diet, exercise, and most existing drugs barely move the needle on Lp(a).15PubMed Central. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease The American Heart Association and other bodies now recommend that everyone have Lp(a) measured at least once in their lifetime, because knowing your level can change how aggressively other risk factors are managed.
Lifestyle Changes and How Much They Actually Help
Lifestyle modification is the first-line treatment for dyslipidaemia and the foundation on which everything else is built, but its effects vary considerably depending on the type of lipid abnormality and the person’s starting point.
Diet changes produce the most reliable improvements in triglycerides and HDL. A Mediterranean-style diet, rich in vegetables, legumes, fish, olive oil, and whole grains, has been shown to reduce total plasma cholesterol and produce favorable shifts in gut bacteria and metabolic byproducts, even when people do not eat fewer calories overall.16Gut. Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake The effect on LDL specifically is more modest and less consistent. One large cohort study found that among people not already on lipid-lowering drugs, higher Mediterranean diet scores were linked to better HDL and lower triglycerides, but not to meaningful reductions in total or LDL cholesterol.17PubMed Central. Impact of Mediterranean Diet on Lipid Composition in the Colaus-PsyColaus Study The honest takeaway is that diet is powerful for triglycerides and HDL but often insufficient on its own to bring high LDL into a safe range, especially when genetics are driving the elevation.
Soluble fiber deserves a mention because it is one of the few dietary components with a consistent, well-quantified effect on LDL. A meta-analysis found that each additional gram of soluble fiber per day (from sources like oats, psyllium, or pectin) lowered LDL by a small but significant amount, and this effect held regardless of study length or background diet composition.18The American Journal of Clinical Nutrition. Cholesterol-lowering effects of dietary fiber: a meta-analysis The reduction per gram is modest, so you need a reasonable daily intake to see a meaningful difference, but it stacks on top of other changes.
Exercise reliably raises HDL cholesterol and lowers triglycerides. Aerobic activity also tends to improve the quality of HDL particles, not just their quantity, making them better at their job of ferrying cholesterol away from artery walls.19PubMed Central. The Impact of Aerobic Exercise on HDL Quantity and Quality: A Narrative Review The effect on LDL is smaller and less predictable, which is why exercise guidelines for dyslipidaemia emphasize its cardiovascular benefits beyond lipid numbers alone.
Medications for Dyslipidaemia
When lifestyle changes are not enough, or when cardiovascular risk is high enough to warrant immediate pharmacological treatment, several classes of drugs are available. They work by different mechanisms and are often combined.
Statins remain the backbone of lipid-lowering therapy. They block an enzyme the liver uses to manufacture cholesterol, forcing the liver to pull more LDL out of the bloodstream. The evidence base for statins is enormous: they reduce both LDL cholesterol and cardiovascular events across a wide range of patient populations. Most people tolerate them well, though muscle aches are a commonly reported side effect. True statin-induced muscle damage (rhabdomyolysis) is rare, but the fear of side effects is a significant driver of non-adherence.
For patients who need additional LDL lowering beyond what statins provide, ezetimibe is often the next addition. It works at the intestinal wall, blocking a transport protein that absorbs cholesterol from food and bile. It is well tolerated and produces meaningful additional LDL reductions when stacked on top of a statin.20PubMed Central. Ezetimibe therapy: mechanism of action and clinical update
PCSK9 inhibitors, given as injections every two to four weeks, represent a more powerful option. They work by preventing a protein called PCSK9 from degrading LDL receptors on liver cells, which keeps more receptors available to clear LDL from the blood. In clinical trials, these drugs reduce LDL by roughly 50 to 60 percent when used alone or in combination with statins, and they reduce cardiovascular events as well.21PubMed Central. PCSK9 inhibitors – mechanisms of action The main barriers to wider use have been cost and the need for regular injections.
Inclisiran, approved in 2021, takes a different approach to the same target. Instead of blocking PCSK9 after it has been made, inclisiran uses a technology called RNA interference to prevent the liver from producing PCSK9 in the first place. The practical advantage is dosing: after two initial injections, patients need only two shots per year, each reducing LDL by about 50 percent when added to maximally tolerated statins.22PubMed Central. Harnessing RNA Interference for Cholesterol Lowering: The Bench-to-Bedside Story of Inclisiran Twice-yearly dosing, administered in a clinic, sidesteps the adherence problems that plague daily pills.
Why So Many People Stop Taking Their Medication
Adherence to lipid-lowering therapy is one of the biggest real-world challenges in managing dyslipidaemia. Because abnormal lipids cause no symptoms, patients often feel fine and question why they need a daily pill. Research into patient perspectives has identified several recurring barriers: people tend to underestimate how vulnerable they are to complications like heart attack and stroke, partly because they feel healthy. They also overestimate how much diet alone can fix the problem, leading them to stop medication in favor of lifestyle changes that may not be enough on their own. Perceived side effects, cost, and poor communication with their prescriber all compound the issue.23PubMed Central. Understanding patients’ perspective of statin therapy: can we design a better approach to the management of dyslipidaemia? A literature review
This is where the cumulative-exposure research described earlier has practical implications. If LDL damage accumulates over decades and every year of elevated exposure adds to your lifetime cardiovascular risk, then stopping a statin for a few years because you feel fine is not a neutral decision. The plaque buildup during that gap does not reverse. Understanding that dyslipidaemia is a slow, silent, and additive process can help reframe the medication conversation from “fixing a number” to “protecting years of future health.”
Screening in Children and Adolescents
Dyslipidaemia is not exclusively an adult problem. Children with FH can have severely elevated cholesterol from birth, and because the arterial damage begins accumulating immediately, early identification matters. The challenge is that FH in children often presents with no risk factors at all; the child is not overweight and has no obvious health concerns. For that reason, universal cholesterol screening in childhood has been recommended by some expert panels to catch cases that targeted screening based on family history would miss.24PubMed Central. Screening and Management of Dyslipidemia in Children and Adolescents
Not all guidelines agree, however. A systematic review of international guidelines found that recommendations for universal childhood screening range from insufficient evidence to support it, to moderate recommendations in favor, with no consensus across countries.25Pediatric Research. Current guidelines on screening, diagnosis and management of dyslipidaemia in childhood: a systematic review What the guidelines do agree on is that once dyslipidaemia is identified in a child, management should begin early, typically starting with diet and exercise and moving to medication in higher-risk cases. For children with FH, statins can be started in the pre-teen years, and the evidence so far supports a favorable safety profile over the medium term.
Supplements and Nutraceuticals
Many people are drawn to “natural” alternatives for managing cholesterol, and a few actually have decent evidence behind them. Red yeast rice extract contains monacolin K, which is chemically identical to the active ingredient in lovastatin, a prescription statin. A systematic review and meta-analysis found that red yeast rice extract effectively lowers LDL cholesterol, and side effects were generally rare and mild, including occasional gastrointestinal symptoms and, very rarely, muscle pain.26PubMed Central. Safety and Efficacy of the Consumption of the Nutraceutical “Red Yeast Rice Extract” for the Reduction of Hypercholesterolemia in Humans: A Systematic Review and Meta-Analysis The catch is that because monacolin K is literally a statin, people who stopped their prescription statin due to side effects may experience the same problems with red yeast rice. And because supplements are not standardized the way drugs are, the actual dose of active ingredient can vary between brands and batches.
Other nutraceuticals with some supporting evidence include plant sterols, soluble fiber (as discussed above), berberine, and artichoke extract. A commentary in a cardiology journal noted that recent lipid guidelines have not explicitly addressed these agents despite meta-analyses supporting their cholesterol-lowering ability, and called for clinicians to recommend only evidence-based nutraceuticals rather than dismissing the category entirely.27PubMed. The complex relationship between cardiologists and lipid-lowering dietary supplements: Hate or love? The practical advice here is that supplements can be a reasonable addition for people with mildly elevated cholesterol who are not yet candidates for prescription drugs, but they are not a substitute for statins in people at high cardiovascular risk.
Why Modern Life Is Particularly Bad for Lipids
An evolutionary lens adds a useful layer to understanding why dyslipidaemia is so common today. Human metabolism evolved in environments defined by intermittent food scarcity, high physical activity, and diets low in refined carbohydrates. The genes that helped our ancestors store energy efficiently and mount strong inflammatory responses to infection are the same genes that, in the context of constant calorie surplus and sedentary living, drive insulin resistance, high triglycerides, and chronic low-grade inflammation in arterial walls.28PubMed Central. An Evolutionary Perspective of Nutrition and Inflammation as Mechanisms of Cardiovascular Disease
A recent narrative review framed atherosclerosis itself as a mismatch disease: biological systems shaped under intermittent metabolic stress are now exposed to chronic, unrelenting activation by modern diets, sedentary behavior, circadian disruption, air pollution, and tobacco. From this perspective, dyslipidaemia is not a random malfunction but a predictable consequence of biology operating outside the conditions it was designed for.29Current Problems in Cardiology. Atherosclerosis as an evolutionary mismatch disease: from ancestral biology to cardiometabolic vulnerability Regional patterns bear this out: the highest rates of low HDL and mixed dyslipidaemia globally are found in the Middle East and Latin America, regions that have undergone rapid nutritional transitions in recent decades.30PubMed Central. Global prevalence of dyslipidemias in the general adult population: a systematic review and meta-analysis The speed of the dietary shift, from traditional eating patterns to ultra-processed, calorie-dense food, appears to matter as much as the diet itself.